LL-37 Peptide Supplier China: COA Review Guide

Define LL-37 at the sequence level

Use the full product name and require the supplier to confirm the sequence, termini and molecular identity reference for the offered material. A short label such as LL37 can be mistyped or attached to an unrelated catalog record. State the physical form, target purity, 5mg nominal content, vial count, packaging and research-use status. The supplier should disclose whether the material is made to stock or synthesized for the order and which site performs purification and release testing.

Review the implications of a longer peptide sequence

Longer or technically demanding peptides can produce synthesis-related fragments and purification challenges, so a buyer should not assume that a generic peptide method is sufficient. Ask how the HPLC method separates relevant impurities and how identity is confirmed. The supplier should explain method scope without making unsupported claims. Compare actual chromatograms, expected molecular information, sample identifiers and acceptance criteria when those records are required. Technical transparency is more valuable than a universal purity slogan.

Connect the COA to the offered LL-37 lot

A batch-specific COA should identify LL-37, the lot, specification, tests, results, units, issue date and authorization. Analytical attachments should use a sample identifier connected to the same lot. If an outside laboratory performed testing, verify report identity and sample custody when material to the decision. Reject generic PDFs without a clear lot relationship. Preserve original issued files and record the reason for any later revision.

Verify 5mg content separately from purity

The catalog presentation is 5mg, but HPLC chromatographic purity does not establish the quantity in each vial. Ask which quantitative method or controlled filling procedure supports nominal content and what tolerance applies. Confirm whether quantity is expressed as net peptide or total lyophilized material. Review filling and reconciliation records when relevant to the specification. Keeping identity, purity and content separate makes wholesale quotations comparable and prevents an impressive percentage from substituting for missing evidence.

Specify protective packaging and transport

Agree vial, closure, label fields, lot code, secondary protection and supplier-supported storage and transport conditions. Do not copy conditions from another peptide without product-specific justification. If monitoring is required, define logger placement, limits and data review. Reconcile the product description across the COA, SDS, label, invoice and packing list. International buyers must verify current local rules through their broker or responsible team and should avoid suppliers promising guaranteed clearance.

Use a risk-based supplier qualification plan

Verify business identity and the roles of manufacturer, laboratory, filler, warehouse and exporter. Use a controlled evaluation order and appropriate independent testing when risk warrants it. At receipt, inspect seals, labels, lot, quantity and package condition and link internal inventory to the supplier batch. Track document accuracy, communication, lead time and complaint response. Before every repeat lot, review new evidence and changes to sequence specification, methods, production site or packaging.

Build a comparable wholesale quotation matrix

Send every candidate the same fields: exact identity, strength, vial count, total quantity, target purity, identity evidence, quantitative-content basis, lot status, packaging, required documents, lead time and shipping term. Mark missing answers as exceptions instead of filling them with assumptions. Keep one-time testing or setup costs separate from recurring unit costs. This gives scientific, purchasing and quality reviewers one controlled record and prevents the lowest-looking price from winning because it describes a smaller scope. Retain the approved matrix with the purchase order and update it with actual receiving performance.

Quality Control: make the specification testable

Define each required attribute, acceptance criterion, method and record before ordering. HPLC commonly supports chromatographic purity and mass spectrometry can support identity, but neither should be interpreted outside method scope. Check the sample identifier, test date, report number, units and relationship to the offered lot. Review the Pure Peptides Core quality-control framework. Batch-specific evidence is stronger than a representative certificate, and unexplained exceptions should be resolved before shipment.

Documentation: establish a pre-shipment gate

List required files in the RFQ and purchase order. Depending on the material, they may include a batch COA, analytical attachments, SDS, specification, supported storage statement, label proof, packing list and invoice. Reconcile product, strength, lot, quantity and revision across records using the documentation support guide. The importer remains responsible for current local requirements. Research-use wording supports clarity but cannot guarantee customs entry or replace buyer due diligence.

Related products and same-category guides

• LL-37 5mg
• MOTS-c Supplier China Guide
• Third-Party Peptide Testing Guide

Frequently asked questions